Nasopharyngeal Carcinoma Treatment Strategies

Nasopharyngeal carcinoma (NPC) is a malignancy arising from the epithelial lining of the nasopharynx and shows a marked prevalence in Southeast Asia, North Africa and parts of the Arctic. Radiotherapy remains the cornerstone of curative treatment for non-metastatic disease, with intensity-modulated radiotherapy (IMRT) enabling highly conformal dose delivery to the primary tumour and involved nodes while sparing adjacent structures. Combined modality approaches, most commonly concurrent chemoradiotherapy, have improved local control and overall survival. Induction chemotherapy followed by chemoradiotherapy is now standard for locoregionally advanced cases, aimed at reducing distant metastasis. In the recurrent or metastatic setting, platinum-based regimens have been supplemented by targeted therapies and immune checkpoint inhibitors, which harness anti-tumour immunity by blocking regulatory receptors on T cells. Patient stratification by plasma Epstein-Barr virus (EBV) DNA levels and other biomarkers allows risk-adapted intensification or de-escalation of therapy, seeking to balance efficacy with toxicity. Recent efforts focus on integrating liquid biopsy for real-time treatment monitoring, refining combinations of immunotherapy and anti-angiogenic agents, and exploiting insights into the tumour microenvironment to overcome drug resistance. Globally, these advances promise to improve outcomes by personalising regimens, reducing long-term sequelae and addressing disparities in access to sophisticated technology.

Research from Nature Portfolio

Real-time monitoring of circulating EBV DNA during sequential induction chemotherapy and chemo-radiotherapy has revealed eight distinct clearance patterns that can be grouped into four prognostic phenotypes: early responders, intermediate responders, late responders and treatment-resistant cases. This stratification correlates with relapse risk and may guide risk-adapted intensification or de-intensification of chemotherapy and radiotherapy. The study demonstrates the utility of liquid biopsy as an on-treatment biomarker, adding prognostic value beyond baseline staging and supporting dynamic treatment adjustment to improve long-term control.

Nasopharyngeal Carcinoma Treatment Strategies publication trend

The graph below shows the total number of articles in nasopharyngeal carcinoma treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Intensity-modulated radiotherapy (IMRT): A form of radiotherapy that delivers highly conformal radiation doses to complex tumour volumes while minimising exposure to adjacent healthy tissues.

Checkpoint inhibitor: A class of immunotherapy agents that block regulatory receptors such as PD-1 on T cells, restoring anti-tumour immune activity.

Programmed death-1 (PD-1) inhibitor: A monoclonal antibody that binds to the PD-1 receptor on T lymphocytes, preventing interaction with its ligands and enhancing immune-mediated tumour destruction.

Epstein-Barr virus (EBV) DNA: Fragments of viral genetic material released into plasma by EBV-associated tumour cells, used as a biomarker for disease burden and treatment response.

Objective response rate (ORR): The proportion of patients in a study whose tumour size is reduced by a predefined amount for a minimum period, reflecting direct antitumour activity.

References

1. Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nature Communications (2019).
2. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). Cancer Cell (2023).
3. Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study. Signal Transduction and Targeted Therapy (2024).
4. Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes. Molecular Cancer (2024).